Amyloid-β associated volume loss occurs only in the presence of phospho-tau

Annals of Neurology

Volumn 70, Issue 4, 2011, Pages 657-661

  Desikan, Rahul S ^a   McEvoy, Linda K ^a   Thompson, Wesley K ^b   Holland, Dominic ^c   Rddey, J Cooper ^c   Blennow, Kaj ^d   Aisen, Paul S ^c   Brewer, James B ^c   Hyman, Bradley T ^e   Dale, Anders M ^a,c,f  

^a Departments of Radiology   (United States)

^b Psychiatry   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTORHINAL CORTEX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUNCTURE; AMNESIA; ATROPHY; BRAIN CORTEX; LONGITUDINAL STUDY; PATHOLOGY;

AGED; AGED, 80 AND OVER; AMNESIA; AMYLOID BETA-PEPTIDES; ATROPHY; CEREBRAL CORTEX; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84855404552     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22509     Document Type: Article

References (20)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356. (Pubitemid 34790756)
2. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 2007;171:1304-1311. (Pubitemid 47582903)
3. Kuchibhotla KV, Goldman ST, Lattarulo CR, et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008;59:214-225. (Pubitemid 352033686)
4. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682-1687. (Pubitemid 18265029)
5. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
6. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-223. (Pubitemid 351978111)
7. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750-754. (Pubitemid 46717684)
8. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-397.
9. Freeman SH, Kandel R, Cruz L, et al. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol 2008; 67:1205-1212.
10. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519. (Pubitemid 43358072)
11. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2007;60:652-656. (Pubitemid 36246085)
12. Buerger K, Ewers M, Pirttilä T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129(Pt 11):3035-3041. (Pubitemid 44684523)
13. Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000;2:199-206. (Pubitemid 32095607)
14. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
15. Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489-497.
16. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310-1323.
17. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69: 1032-1042.
18. Hampel H, Blennow K, Shaw LM, et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010;45:30-40.
19. Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011;108:5819-5824.
20. Ittner LM, Götz J. Amyloid-β and tau-α toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011;12:65-72.